Athira Pharma (NASDAQ:LONA) Price Target Cut to $15.00 by Analysts at Mizuho

Athira Pharma (NASDAQ:LONA) had its target price decreased by analysts at Mizuho from $16.00 to $15.00 in a report released on Wednesday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Mizuho’s price objective would suggest a potential upside of 84.05% from the company’s previous close.

Several other equities research analysts have also weighed in on LONA. Piper Sandler assumed coverage on Athira Pharma in a report on Wednesday, May 27th. They issued an “overweight” rating and a $20.00 price objective for the company. Wall Street Zen raised shares of Athira Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Citizens Jmp cut their target price on shares of Athira Pharma from $18.00 to $17.00 and set a “market outperform” rating for the company in a research report on Monday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Athira Pharma in a research note on Friday, August 7th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $17.33.

Athira Pharma Stock Performance

NASDAQ LONA traded down $0.02 on Wednesday, hitting $8.15. 9,052 shares of the stock traded hands, compared to its average volume of 53,470. The business’s fifty day moving average is $8.24 and its two-hundred day moving average is $8.29. Athira Pharma has a 12 month low of $3.52 and a 12 month high of $14.21. The firm has a market capitalization of $76.53 million, a price-to-earnings ratio of -1.94 and a beta of 2.05.

Athira Pharma (NASDAQ:LONA) last issued its earnings results on Friday, August 14th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.20). Analysts expect that Athira Pharma will post -3.12 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Focus Partners Wealth bought a new stake in Athira Pharma during the third quarter valued at approximately $35,000. Jane Street Group LLC purchased a new position in Athira Pharma in the 4th quarter worth approximately $100,000. Renaissance Technologies LLC increased its holdings in shares of Athira Pharma by 44.7% in the 4th quarter. Renaissance Technologies LLC now owns 75,147 shares of the company’s stock worth $569,000 after buying an additional 23,223 shares during the last quarter. Seven Fleet Capital Management LP bought a new position in shares of Athira Pharma in the 4th quarter worth $969,000. Finally, Millennium Management LLC purchased a new stake in shares of Athira Pharma during the 4th quarter valued at $2,456,000. 57.12% of the stock is currently owned by institutional investors.

Athira Pharma Company Profile

Athira Pharma, Inc is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).

The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system.